RTM receives marketing authorisation for Fludeoxyglucose (18F)
We are happy to announce that RTM has received marketing authorization for 18F-FDG of 17 July 2018.
Fludeoxyglucose (18F) RTM 200 MBq/ml, solution for injection will become commercially available in The Netherlands in October, with roll-out to Belgium and Germany planned in 2019.
- Interesting? Share this article
Other news
First liver cancer patient treated with microspheres irradiated in TU Delft
Radboud Translational Medicine will perform the dispensing of below product. The production and dis...
18F-FDOPA now available
Fluorodopa (18F) is now available for clinical studies and - with doctor's certificate - for routine...
Upcoming event
From October 15 to October 19, Radboud translational medicine will attend the 29th annual congress o...
1st production QuiremSpheres
On May 21st, the first patient dosis of QuiremSpheres was processed at RTM and then shipped to the s...
Interested in a collaboration?
Contact us to discuss the possibilities.